Company Filing History:
Years Active: 2007
Title: Thomas G Chasteen: Innovator in Chemiluminescent Technology
Introduction
Thomas G Chasteen is a notable inventor based in Huntsville, TX (US). He has made significant contributions to the field of biotherapy through his innovative work in chemiluminescent light sources. His inventions focus on utilizing visible light to combat pathogenic microorganisms, showcasing his commitment to advancing medical technology.
Latest Patents
Chasteen holds a patent for a "Chemiluminescent light source using visible light for biotherapy." This invention relates to devices and methods designed to kill or debilitate pathogenic microorganisms present in or on a patient's body. The chemiluminescent light source emits electromagnetic radiation with predetermined wavelengths in the visible spectrum. These light wavelengths are specifically chosen for their ability to be absorbed by naturally occurring photosensitive chemicals produced by the patient's body. This innovative approach has the potential to enhance therapeutic outcomes in medical treatments.
Career Highlights
Throughout his career, Thomas G Chasteen has demonstrated a strong dedication to research and development in the medical field. His work at Lumerx, Inc. has positioned him as a key player in the advancement of biotherapy technologies. With a focus on practical applications of his inventions, Chasteen continues to contribute to the improvement of patient care.
Collaborations
Chasteen has collaborated with notable professionals in his field, including Marc Joshua Tolkoff and Philip Stephen Levin. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Thomas G Chasteen is a pioneering inventor whose work in chemiluminescent technology is making strides in the field of biotherapy. His dedication to improving medical treatments through innovative inventions is commendable. The impact of his contributions will likely be felt in the medical community for years to come.